Medullary thyroid carcinoma (MTC) · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	aggressive
Linked regimen	`None`

ID	`IND-MEN2-CARRIER-INTENSIFIED`
Type	Indication
Status	reviewed 2026-05-18 \| pending_clinical_signoff
Diseases	`DIS-MTC`
Sources	`SRC-ATA-THYROID-2015` `SRC-NCCN-THYROID-2025`

Notes

STUB — v0.2-B confirmed-carrier intensified track (MEN2). Sibling — IND-MEN2-CARRIER-SURVEILLANCE. §15.2 C4 ≥2-tracks invariant.

Used By

Actionability

BMA-CALCITONIN-MTC-MEN2-SURVEILLANCE - Serum calcitonin is a highly specific biomarker for medullary thyroid carcinoma (MTC) — p...
BMA-METANEPHRINES-PHEO-VHL-MEN2-SURVEILLANCE - Plasma free metanephrines are the gold-standard biochemical test for pheochromocytoma and...

Algorithms

ALGO-MEN2-CARRIER-PROPHYLACTIC-THYROIDECTOMY-TIMING - ALGO-MEN2-CARRIER-PROPHYLACTIC-THYROIDECTOMY-TIMING

Indication

IND-MEN2-CARRIER-SURVEILLANCE - IND-MEN2-CARRIER-SURVEILLANCE

Red flag

RF-MEN2-CONFIRMED-CARRIER - Confirmed germline pathogenic / likely-pathogenic variant in the RET proto-oncogene — MEN...